SPTX outlines Glyph platform oral-therapy progress for depression, anxiety
SPTX says its Glyph platform targets oral bioavailability and liver-toxicity challenges. Lead programs GlyphAllo and GlyphAgo target depression and anxiety, with registration-enabling trials planned.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.